PMID- 34610840
OWN - NLM
STAT- MEDLINE
DCOM- 20220214
LR  - 20220214
IS  - 1465-993X (Electronic)
IS  - 1465-9921 (Print)
IS  - 1465-9921 (Linking)
VI  - 22
IP  - 1
DP  - 2021 Oct 5
TI  - Validation of a derived version of the IPF-specific Saint George's Respiratory 
      Questionnaire.
PG  - 259
LID - 10.1186/s12931-021-01853-2 [doi]
LID - 259
AB  - BACKGROUND: Health-related quality of life (HRQL) is impaired in patients with 
      idiopathic pulmonary fibrosis (IPF). HRQL is often measured using the St. 
      George's Respiratory Questionnaire (SGRQ) despite the development of an 
      IPF-specific version (SGRQ-I). Using data from a real-world cohort of patients 
      with IPF, we aimed to transform SGRQ into a derived version of SGRQ-I, 
      SGRQ-I(der), to examine the cross-sectional and longitudinal validity of 
      SGRQ-I(der) and to compare SGRQ-I(der) to SGRQ-I. METHODS: Based on results from 
      SGRQ, SGRQ-I(der) was derived applying the algorithm used to develop SGRQ-I. Of 
      the 50 items in SGRQ, 34 items were retained in SGRQ-I(der). Response options for 
      seven items were collapsed and minor adjustments were made to the weights of two 
      items after correspondence with the developers of SGRQ-I. Cross-sectional 
      validation, responsiveness and minimal clinically important difference (MCID) 
      were assessed by comparison to other HRQL instruments, pulmonary function tests 
      and 6-min walk test performed at baseline, 6 and 12 months. Furthermore, the 
      association between SGRQ-I(der) scores and mortality was examined. RESULTS: A 
      total of 150 IPF patients participated and 124 completed follow-up at 12 months. 
      SGRQ-I(der) performed comparably to SGRQ-I with a high concurrent validity, good 
      test-retest reliability and high known-groups validity. SGRQ-I(der) was 
      responsive to change in HRQL and physiological anchors. MCID of SGRQ-I(der) for 
      improvement and deterioration was 3.5 and 5.7, respectively. SGRQ-I(der) scores 
      were associated with mortality in both univariate (HR 1.82, 95% CI 1.42-2.34 per 
      20-point increase) and multivariate analyses (HR 1.57, 95% CI 1.20-2.05 per 
      20-point increase). CONCLUSIONS: The SGRQ-I(der) is a valid, reliable and 
      responsive HRQL instrument in patients with IPF and has psychometric properties 
      comparable to SGRQ-I. Thus, SGRQ results can reliably be transformed into the 
      SGRQ-I(der). The MCID estimates were calculated for improvement and deterioration 
      separately. Increasing SGRQ-I(der) score was associated with increased mortality.
CI  - (c) 2021. The Author(s).
FAU - Prior, Thomas Skovhus
AU  - Prior TS
AUID- ORCID: 0000-0002-0668-8454
AD  - Center for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, 
      Aarhus University Hospital, Aarhus, Denmark. thbjer@rm.dk.
FAU - Hoyer, Nils
AU  - Hoyer N
AD  - Department of Respiratory Medicine, Herlev-Gentofte University Hospital, 
      Copenhagen, Denmark.
FAU - Shaker, Saher Burhan
AU  - Shaker SB
AD  - Department of Respiratory Medicine, Herlev-Gentofte University Hospital, 
      Copenhagen, Denmark.
FAU - Davidsen, Jesper Romhild
AU  - Davidsen JR
AD  - South Danish Center for Interstitial Lung Diseases (SCILS), Department of 
      Respiratory Medicine, Odense University Hospital, Odense, Denmark.
FAU - Hilberg, Ole
AU  - Hilberg O
AD  - Department of Respiratory Medicine, Vejle Hospital, Vejle, Denmark.
FAU - Patel, Haridarshan
AU  - Patel H
AD  - Immensity Consulting, Inc., Chicago, IL, USA.
FAU - Bendstrup, Elisabeth
AU  - Bendstrup E
AD  - Center for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, 
      Aarhus University Hospital, Aarhus, Denmark.
LA  - eng
GR  - 118860/TrygFonden/
PT  - Comparative Study
PT  - Journal Article
PT  - Validation Study
DEP - 20211005
PL  - England
TA  - Respir Res
JT  - Respiratory research
JID - 101090633
SB  - IM
MH  - Cross-Sectional Studies
MH  - Health Status
MH  - Humans
MH  - Idiopathic Pulmonary Fibrosis/*diagnosis/mortality/physiopathology/therapy
MH  - Longitudinal Studies
MH  - Lung/*physiopathology
MH  - Mental Health
MH  - Minimal Clinically Important Difference
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Psychometrics
MH  - *Quality of Life
MH  - Reproducibility of Results
MH  - Respiratory Function Tests
MH  - Severity of Illness Index
MH  - *Surveys and Questionnaires
MH  - Time Factors
MH  - Walk Test
PMC - PMC8491388
OTO - NOTNLM
OT  - IPF-specific version of St. George's Respiratory Questionnaire
OT  - Idiopathic pulmonary fibrosis
OT  - Quality of life
OT  - St. George's Respiratory Questionnaire
OT  - Validation
COIS- For the current work, TSP has received an unrestricted grant from Boehringer 
      Ingelheim and TSP and HP have received personal fees from Galapagos. Outside the 
      current work, TSP has received personal fees from Boehringer Ingelheim, JRD has 
      received personal fees and non-financial support from Boehringer Ingelheim and 
      Roche, and EB has received personal fees from Galapagos and personal fees and 
      grants from Boehringer Ingelheim and Roche. NH, OH, and SBS have nothing to 
      declare.
EDAT- 2021/10/07 06:00
MHDA- 2022/02/15 06:00
PMCR- 2021/10/05
CRDT- 2021/10/06 05:33
PHST- 2021/05/31 00:00 [received]
PHST- 2021/09/26 00:00 [accepted]
PHST- 2021/10/06 05:33 [entrez]
PHST- 2021/10/07 06:00 [pubmed]
PHST- 2022/02/15 06:00 [medline]
PHST- 2021/10/05 00:00 [pmc-release]
AID - 10.1186/s12931-021-01853-2 [pii]
AID - 1853 [pii]
AID - 10.1186/s12931-021-01853-2 [doi]
PST - epublish
SO  - Respir Res. 2021 Oct 5;22(1):259. doi: 10.1186/s12931-021-01853-2.